Feb 26, 2020 8:30am EST Veru Initiates Phase 2 Clinical Trial of VERU-111, First-in-Class, Oral, Advanced Prostate Cancer Drug
Feb 12, 2020 6:30am EST Veru Continues Strong Positive Sales Momentum in Fiscal 2020 First Quarter; Net Revenues Increase 66%, Gross Profit Up 57%
Feb 05, 2020 8:30am EST Veru to Report Fiscal 2020 First-Quarter Financial Results, Host Conference Call on February 12th
Jan 21, 2020 8:30am EST Veru Announces Acceptance of Two Abstracts for Presentation at the Genitourinary Cancer Symposium in February 2020
Jan 13, 2020 8:00am EST Veru Announces Positive Top-Line Interim Data from Phase 2 Clinical Trial of Zuclomiphene to Treat Hot Flashes in Men with Prostate Cancer on Androgen Deprivation Therapy
Dec 12, 2019 6:30am EST Veru Reports Fiscal 2019 Full-Year Net Revenues Doubled, Gross Profit Up 147%
Dec 05, 2019 8:30am EST Veru to Report Fiscal 2019 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 12th
Oct 02, 2019 6:30am EDT Veru Announces Full Enrollment of Phase 2 Trial in Men with Prostate Cancer Treatment Induced Hot Flashes
Aug 28, 2019 8:30am EDT Veru to Participate at Three Upcoming Healthcare Investor Conferences in New York
Aug 27, 2019 8:30am EDT Veru to Ring NASDAQ Closing Bell on September 4th to Kick Off National Prostate Cancer Awareness Month
